Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 5/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.45 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568628 | 1.00 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL1384803 | 1.00 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3868250 | 1.00 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL13866886 | 1.00 | HPGD (0.47) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3965258 | 0.93 | HPGD (0.42) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL1385240 | 0.92 | ITGB3 (0.51) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL2572450 | 0.92 | ITGB3 (0.51) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3972336 | 0.91 | PIM1 (0.43) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3972338 | 0.91 | PIM1 (0.43) | HPGDAKR1B1PIM1PIM2NPC1 | |
| SCHEMBL3965304 | 0.91 | REN (0.42) | HPGDAKR1B1PIM1PIM2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848700-B1 | SALTS OF (S)-2-AMINO-3-{4-[4-(2,4-DIOXO-THIAZOLIDIN-5-YLMETHYL)-PHENOXY]-PHENYL}-PROPIONIC ACID AND ITS METHYL ESTER AS INTERLEUKIN INHIBITORS FOR THE TREATMENT OF OBESITY OR DIABETES | BEXEL PHARMACEUTICALS INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-7521465-B2 | Diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1848700-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE]THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | Bexel Pharmaceuticals Inc (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006089225-A1 | 5- [4- (4- (2 -AMINO- 2 -METHOXYCARBONYLETHYL) PHENOXY) BENZILIDENE] THIAZOLIDIN-2 , 4-DION E DERIVATIVES AND RELATED COMPOUNDS FOR REDUCING GLUCOSE, CHOLESTEROL AND TRIGLYCERIDE LEVELS IN PLASMA | BEXEL PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20050288341-A1 | Novel diphenyl ether derivatives | BEXEL PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288341-A1 | Novel diphenyl ether derivatives | GPR119, FABP4, PNLIP | HPGD 3604/4885AKR1B1 1527/4885PIM1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.